Fig. 2From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaKaplan-Meier curves for DOR (a) and DOSD (b) during VEM1-IPI. The median DOR was 23.1 months (95 % CI: 5.03–not evaluable), and the median DOSD was 5.2 months (95 % CI: 3.98–14.75)Back to article page